Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Academic Journal of Second Military Medical University》 2015-01
Add to Favorite Get Latest Update

Small bronchoscopic biopsy specimens for detecting EGFRgene mutations in advanced lung adenocarcinoma

NIE Yun-qiang;LI Cui-yun;LI Na;ZHANG Xiao-yan;WANG Hui;GUO Da-cai;HAN Ping;L Xin;LIU Shu-ling;WANG Chang-ling;XU Xin-yi;Department of Respiratory Medicine,People's Hospital of Linyi;Department of Oncology,People's Hospital of Linyi;  
Objective To examine epidermal growth factor receptor(EGFR)gene mutations in small bronchoscopic biopsy specimens,so as to provide guidance for clinical targeted therapy.Methods Fifty-six female patients with advancedstage Ⅲ B-Ⅳ lung adenocarcinoma underwent endoscopic endobronchial biopsy of tumor tissues or transbronchial needle aspiration of mediastinal and hilar lymph nodes.Under the endoscope,20 patients underwent only bronchial biopsy,28 underwent only transbronchial needle aspiration(TBNA)lymph node biopsy,and 8underwent both endobronchial biopsy and TBNA biopsy of mediastinal and hilar lymph nodes.A total of 64 specimens were collected and were subjected to detection of EGFR gene mutations after confirmation of lung adenocarcinoma.The specimens were then divided into endobronchial metastasis group and lymph node metastasis group,and the mutations of exons 19 and 21were detected and the clinical efficacy of targeted therapy was analyzed.Results Exon 19 had higher positive rate in the endobronchial metastasis group(χ2=4.304,P=0.038),and exon 21 had higher positive rate in lymph node metastasis group(χ2=18.727,P=0.000).A total of 24 cases were included for the clinical efficacy assessments:10had endobronchial metastasis(exon 19 mutations in 8cases,21 exon in 2cases),with the disease control rate being 90%(9/10)and median progression-free survival period being 14.8 months;14patients had lymph node metastasis(19exon 3cases,21 exon 11cases),with the disease control rate being 78.57%(11/14)and the median progression-free survival period being 9.2 months;the disease control rates were not significantly different between the two groups(P0.05)and the median progression-free survival periods were significantly different between the two groups(χ2= 4.134,P=0.042).Conclusion Mutations of different EGFRexons might relate to the metastasis forms of female advanced lung adenocarcinoma,with exon 19 prone to endobronchial metastasis and exon 21 to lymph node metastasis.Targeted therapy for patients with endobronchial metastasis has a better outcome than that for patients with lymph node metastasis.
【Fund】: 临沂市科技发展计划项目(201313006)~~
【CateGory Index】: R734.2
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Co-citations】
China Proceedings of conference Full-text Database 1 Hits
1 Zhengbo Song~(1,2),Huineng Zhu~(2,3),Zhenying Guo~(2,3),Wei Wu~(2,3),Wenyong Sun ~(2,3),Yiping Zhang~(1,2) 1 Department of Chemotherapy,Zhejiang Cancer Hospital,Hangzhou 310022, China 2 Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang province,Hangzhou 310022,China 3 Department of Pathology,Zhejiang Cancer Hospital,Hangzhou 310022, China;Prognostic value of the IASLC/ATS/ERS classification in stageⅠlung adenocarcinoma patients[A];[C];2013
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved